BEST OF HEMATOLOGY 2024: Keynote Presentation: VTE Update – Dr. Adam Cuker
OR
Chair
Dr. Martina Trinkaus
Dr. Matthew Seftel
Panelist
Dr. Adam Cuker
Studies/trials discussed:
- Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data
- Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease: A Population-Based Study
- Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial
- RCT Results: 6 Weeks vs 3 Months of Rivaroxaban for Isolated Distal DVT
- Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial
- Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials
- Factor XIa Inhibitors as New Anticoagulants
- Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
- Phase III Cancer associated VTE
- Prevention of catheter associated thrombosis in cancer patients receiving chemotherapy
